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Abstract
Nontuberculous mycobacteria (NTM) are being increasingly iso-
lated in clinical laboratories and present technical and therapeu-
tic challenges. In the present study, we report our experience
with the identiﬁcation of NTM received from 12 Lisbon hospitals
over a 3-year period using GenoType Mycobacterium (CM/AS)
assays (HAIN Lifescience GmbH, Nehren, Germany). Together,
the two kits identiﬁed 96.6% of all NTM isolates tested. Among
the 18 NTM species identiﬁed, Mycobacterium avium complex
was the most frequent, although it accounted for only 34% of all
NTM. Introducing these methods for the rapid identiﬁcation of
NTM highlights the importance of NTM as potential pathogens
and assisted the selection of adequate therapy.
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Although Mycobacterium tuberculosis is the main cause of
mycobacteriosis in humans, other species of mycobacteria
may also cause infection [1,2]. The increasing importance of
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nontuberculous mycobacteria (NTM) in the clinical laboratory
is now generally recognized [3–6]. Among the many factors
that may contribute to such an increase are the HIV/AIDS
pandemics and other immunocompromising diseases, the
technical improvements in NTM recovery and identiﬁcation,
the increased interest in NTM identiﬁcation and the improve-
ment of public health services for tuberculosis [4,5].
Conventional identiﬁcation of mycobacteria is achieved by
standard culture and biochemical methods, all of which are
time consuming. The rise in NTM isolation demands faster
methods for their identiﬁcation and for selection of appropri-
ate therapy. In the present study, the GenoType Mycobacte-
rium CM and AS assays (HAIN Lifescience GmbH, Nehren,
Germany) were jointly employed for the identiﬁcation of
NTM present in isolates received in our laboratory. These
genetically based assays are designed for identifying the clini-
cally most relevant mycobacterial species isolated in culture.
From 1 January 2005 to 31 December 2007, our labora-
tory received a total of 1192 acid-fast bacilli (AFB) isolates
from 1174 patients presenting with presumptive active
mycobacteriosis at 12 hospitals of the Greater Lisbon Area
(Portugal). All isolates were processed for acid-fast staining
(Ziehl-Neelsen stain) and inoculated into MGIT tubes of the
BACTEC MGIT 960 System (Becton-Dickinson Diagnostic
Instrument Systems, Towson, MD, USA) [7]. When neces-
sary, decontamination was carried out by the conventional
NaOH-NALC method [8].
M. tuberculosis strains isolated from culture were identi-
ﬁed by the Accuprobe system (Gen-Probe Inc., San Diego,
CA, USA). Fully-grown AFB cultures, negative for M. tubercu-
losis, were identiﬁed by GenoType Mycobacterium (CM/AS)
kits. The experimental procedure involves the isolation of
DNA from cultures using the QIAamp DNA mini kit (Qiagen
GmbH, Hilden, Germany), PCR ampliﬁcation of a region of
the 23S rRNA gene region [9] with biotinylated primers, and
reverse hybridization of the biotin-labelled amplicons with
probes immobilized on membrane strips. Identiﬁcation is
achieved by comparing the hybridization patterns obtained
with those provided by an interpretation chart. Together,
the GenoType Mycobacterium CM (Common Mycobacteria)
and the GenoType Mycobacterium AS (Additional Species)
kit allow the identiﬁcation of 30 species, listed in Table 1.
Mycobacteria not identiﬁable by any of these systems were
identiﬁed by partial 16S rDNA sequencing using the primers
27f and 519r as previously described [10]. When available
for a given species, NTM Accuprobe probes were used for
comparison with the GenoType CM results.
During the 3-year period, out of 1192 specimens received,
1181 were identiﬁed as members of the Mycobacterium
genus, whereas the 11 non-mycobacterial acid-fast bacilli
cultures were identiﬁed as Nocardia spp. (nine isolates), Tsuk-
amurella (one isolate) and Rhodococcus (one isolate) by 16S
rRNA gene sequencing. Among the 1181 mycobacterial
cultures, 1032 (87.4%) were positive for the M. tuberculosis
complex. The remaining 149 cultures were NTM, corre-
sponding to 12.6% of the total number of cultures from
which mycobacteria were isolated. During the study period,
NTM prevalence increased steadily, starting with 8.7% in
2005 and rising to 15.2% in 2007.
The joint use of the CM and AS kits identiﬁed 96.6% of all
NTM isolates tested; these results are comparable to those
reported elsewhere [9, 11–15]. The GenoType Mycobacte-
rium CM system identiﬁed 136 out of 149 NTM cultures
tested. Of the remaining 13 isolates, eight were identiﬁed
with the GenoType AS kit (Table 1). When available, there
was complete agreement between the Accuprobe identiﬁca-
tion result and that provided by the GenoType CM system
(data not shown). Sequencing of the 5¢-termini of 16S rDNA
identiﬁed the remaining ﬁve isolates as Mycobacterium
arupense/Mycobacterium nonchromogenicum (three isolates)
and Mycobacterium terrae (two isolates).
A total of 18 NTM species were identiﬁed (Table 1).
Although Mycobacterium avium was the most frequently found
species, the relatively low percentage of M. avium among all of
the NTM isolates was one of the important ﬁndings of the pres-
ent study. Even if we consider theM. avium complex (M. avium
plus Mycobacterium intracellulare isolates), it would account for
only one-third (34%) of all NTM isolates received in our labora-
tory. The species distribution of the remaining NTM was in
agreement with that reported earlier in a multicountry survey
on the frequency and distribution of NTM, which included Por-
tugal [4], except for Mycobacterium kansasii, fourth among the
NTM species, together with M. intracellulare and Mycobacterium
fortuitum, whereas, in the previous study it was not found
among the Portuguese isolates [4].
Although the NTM-containing specimens were mainly
respiratory (Table 1), over 10% of NTM were isolated from
sterile sources, namely blood and cerebral-spinal ﬂuids. The
isolation of NTM from these sources is particularly relevant
because it illustrates situations where the ability of the labo-
ratory to identify NTM rapidly and precisely plays a major
role in the clinical outcome of the infection. In the present
study, all NTM identiﬁed were considered to be clinically rel-
evant, either as the cause of infection or as confounders of
diagnosis and therapeutics.
Among the different methods available for NTM identiﬁca-
tion, the Accuprobe system, based on a hybridization protec-
tion assay with DNA probes, is the one most widely used
because of its accuracy and rapidity. In our laboratory, the
Accuprobe system remains the standard for identiﬁcation of
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isolates from the M. tuberculosis complex. However, the
increasing isolation of NTM by the collaborating hospitals
proved challenging to our work algorithm. The Accuprobe
system is currently limited to the identiﬁcation of ﬁve
species/complexes (M. tuberculosis complex, M. avium,
M. intracellulare, or the M. avium complex as a whole,
M. kansasii and Mycobacterium gordonae) and, although these
correspond to the most frequently isolated mycobacteria,
these probes failed to identify 40.2% of all NTM isolated and
identiﬁed in the present study by the combined use of the
CM and AS kits.
An important advantage provided by the GenoType kits is
the possibility to detect mixed infections. In the present
study, such mixed infections were detected in sputa, blood,
and urine. The co-existing species isolated from these speci-
mens were M. tuberculosis and M. avium, M. gordonae or
Mycobacterium abcessus. The co-isolation of M. tuberculosis
and other mycobacteria and their distinction was highly rele-
vant for the selection of therapy.
The GenoType methodology provided identiﬁcation within
6 h. The major drawbacks were cost (approximately €40
per test) and the need to have a fully-grown culture to
obtain reliable results. Despite the advantages provided by
molecular methods, conventional methods for the identiﬁca-
tion of NTM must be retained and judiciously used when
necessary.
In countries with a high incidence of tuberculosis and, par-
ticularly, multidrug-resistant M. tuberculosis (MDR-TB) such
as Portugal [16], therapeutic failure with isoniazid and rifam-
picin is anticipated to be the result of an MDR-TB strain.
Because many NTM species are resistant to these drugs [3],
the identiﬁcation of the mycobacteria causing therapeutic fail-
ure (MDR-TB vs. NTM) is of major importance [17]. This
has been appreciated by the clinicians at the collaborating
hospitals and has resulted in an increased awareness of the
importance of being able to identify NTM rapidly as potential
pathogens and the key role played by the laboratory in
assisting the selection of therapeutic modality.
TABLE 1. Nontuberculous mycobacteria species identiﬁed with the Genotype CM/AS systems during the 3-year period
Species/complex identiﬁable
Identiﬁed in
the present
study
Number of
isolates
(frequency)a Source (number of isolates)
GenoType Mycobacterium CM
Mycobacterium avium spp. Yes 37 (24.8%) Blood culture (14); sputum (8); bronchial secretions (5); bronchoalveolar lavage (3);
articular ﬂuid (1); biopsies (2); myeloculture (1); urine (1); Gastric ﬂuid (1); pus (1)
Mycobacterium gordonae Yes 23 (15.4%) Sputum (20); gastric ﬂuid (2); bronchial secretions (1)
Mycobacterium fortuitum Yes 14 (9.4%) Sputum (10); bronchial aspirate (3); bronchial secretions (1)
Mycobacterium intracellulare Yes 14 (9.4%) Sputum (8); bronchial secretions (2); bronchoalveolar lavage (1); gastric ﬂuid (1);
articular ﬂuid (1); urine (1)
Mycobacterium kansasii* Yes 14 (9.4%) Sputum (8); bronchial secretions (4); bronchoalveolar lavage (1); synovial ﬂuid (1)
Mycobacterium chelonae Yes 10 (6.7%) Sputum (7); bronchial secretions (1); biopsies (1); pus (1)
Mycobacterium xenopi Yes 9 (6%) Sputum (6); bronchial aspirate (1) bronchial secretions (1); bronchoalveolar lavage (1)
Mycobacterium peregrinum Yes 7 (4.7%) Sputum (5); biopsies (1); bronchial secretions (1)
Mycobacterium abscessus Yes 6 (4%) Sputum (4); bronchoalveolar lavage (1); gastric ﬂuid (1)
Mycobacterium scrofulaceum Yes 1 (0.7%) Sputum (1)
Mycobacterium malmoense Yes 1 (0.7%) Sputum (1)
Mycobacterium interjectum No – –
Mycobacterium marinum/
Mycobacterium ulcerans
No – –
Mycobacterium tuberculosis complex Not applicableb – –
Geno type Mycobacterium AS
Mycobacterium simiae Yes 1 (0.7%) Blood culture (1)
Mycobacterium mucogenicum Yes 4 (2.6%) Cerebral-spinal ﬂuid (2); Bronchoalveolar lavage (1); biopsies (1)
Mycobacterium lentiﬂavum Yes 1 (0.7%) Sputum (1)
Mycobacterium heckeshornense Yes 1 (0.7%) Sputum (1)
Mycobacterium celatum Yes 1 (0.7%) Bronchial secretions (1)
Mycobacterium smegmatis No – –
Mycobacterium goodii No – –
Mycobacterium genavense No – –
Mycobacterium szulgai/
Mycobacterium intermedium
No – –
Mycobacterium phlei No – –
Mycobacterium haemophilum No – –
Mycobacterium kansasii* Not applicablec – –
Mycobacterium ulcerans No – –
Mycobacterium gastri No – –
Mycobacterium asiaticum No – –
Mycobacterium shimoidei No – –
*Both kits are able to identify M. kansasii, for which Genotype AS distinguishes four possible hybridization patterns.
The AS kit distinguishes M. ulcerans.
aAmong a total of 149 nontuberculous mycobacteria isolates that included ﬁve isolates not identiﬁable by any of the kits (see text).
bAll M. tuberculosis complex isolates were identiﬁed by Accuprobe.
cAll M. kansasii isolates were identiﬁed with the Genotype CM kit.
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Abstract
Thirty-six multidrug-resistant (MDR) Mycobacterium tuberculosis
isolates collected in Japan were examined for pyrazinamide sus-
ceptibility and pyrazinamidase activity, and analysed by pncA
sequencing and a hybridization-based line probe assay (LiPA),
which was used to detect pncA mutations for the rapid identiﬁ-
cation of pyrazinamide-resistant isolates. Pyrazinamide resistance
was found in 19 (53%) of them. All pyrazinamide-resistant iso-
lates had no pyrazinamidase activity and at least one mutation in
pncA. Among the pncA mutations, 11 had not been previously
reported. The results of the LiPA were fully consistent with the
DNA sequencing results. A majority of MDR M. tuberculosis iso-
lates in Japan were resistant to pyrazinamide.
Keywords: Line probe assay, multidrug resistance, Mycobacte-
rium tuberculosis, pncA, pyrazinamide
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